OBJECTIVE: This paper aims to explore the impact of checkpoint inhibitors, a novel cancer therapy, on cancer nursing, including aspects of education, research, and practical application. METHODS: Our discussion is grounded in clinical expertise and supported by relevant literature from peer-reviewed journals. RESULTS: This focused discussion on the nursing implications of immune checkpoint inhibitors as a novel cancer therapy highlights a significant transformation in cancer nursing practice. There is a pressing need to enhance the skills of the cancer nursing workforce and expand their knowledge regarding the mechanisms of action of immunotherapies, their toxicity profiles, including late effects, potential drug interactions, principles of administration, and the assessment and management of immune-related adverse reactions. The introduction of immunotherapy necessitates not only a collaborative multidisciplinary approach but also a multispecialty strategy due to the diverse nature of immune-related side effects affecting various body systems. The complexity of managing toxicities associated with immunotherapy, particularly when used in conjunction with other treatment modalities, imposes additional costs and strains on existing healthcare services. Some organizations, depending on their healthcare models, encounter challenges when these additional services are not appropriately funded. CONCLUSION: In the case of immunotherapy as a novel cancer treatment, there are clear benefits to patients in terms of survival, but this has come with safety issues for patients and staff. The nursing workforce is key to safety around immunotherapy with regard to the safe delivery of treatment and the management of toxicity. This cannot be achieved without the education of the nursing workforce and underpinning research.